Pharmaceutical composition for treating central nervous system inflammatory demyelinating diseases and application of pharmaceutical composition in combined administration

A demyelinating disease, central nervous system technology, applied in nervous system diseases, drug combinations, allergic diseases, etc., can solve the problems of incomplete elucidation of the pathogenesis and lack of specific drug treatment.

Active Publication Date: 2015-04-01
THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Inflammatory demyelinating diseases of the central nervous system are a very common type of central nervous system autoimmune diseases mediated by T cells, mainly including multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), sub Acute neuromyelitis optica (SMON), concentric sclerosis, central allergic diseases induced by various reasons (such as after infection with various biological pathogens, after vaccination, heterosexual protein allergy, and drug or chemical allergic reaction) ( Such as acute demyelinating leukoencephalopathy and acute demyelinating myelitis), the pathogenesis has not been fully elucidated, and there is currently a lack of specific drug treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating central nervous system inflammatory demyelinating diseases and application of pharmaceutical composition in combined administration
  • Pharmaceutical composition for treating central nervous system inflammatory demyelinating diseases and application of pharmaceutical composition in combined administration
  • Pharmaceutical composition for treating central nervous system inflammatory demyelinating diseases and application of pharmaceutical composition in combined administration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1. Study on the Mechanism of SCH in Treating Central Nervous System Inflammatory Demyelinating Diseases

[0066] 1. Making of EAE model

[0067] Of 48 C57BL / 6 mice, 42 of them were randomly selected, and each mouse was anesthetized with 0.5% pentobarbital (0.27ml) intraperitoneally, and then intradermally injected with antigen at four points at the base of the tail, both sides of the abdomen, and the neck. Emulsion (mixed with myelin oligodendrocyte glycoprotein (MOG) and complete Freund's adjuvant), inject 0.05ml at each point, 0.2ml in total, and then intraperitoneally inject pertussis toxin immediately and 48 hours later. , PT) 500ng to induce an immune response to create a classic EAE model.

[0068] 2. Animal Grouping and Drug Intervention

[0069] Six mice that were not injected with MOG antigen emulsion were used as the normal control group; 42 EAE model mice that were injected with MOG antigen emulsion were randomly divided into DMSO control group, inc...

Embodiment 2

[0104] Example 2. Combined use of 2-BFI and SCH in the treatment of central nervous system inflammatory demyelinating diseases

[0105] 1. Making of EAE model

[0106]There were 64 C57BL / 6 mice, and each mouse was anesthetized with 0.5% pentobarbital 0.27ml intraperitoneally, and then injected MOG antigen emulsion intradermally at the base of the tail, both sides of the abdomen, and the neck (injection at each point) 0.05ml, 0.2ml in total). Immediately and 48 hours after the injection, 500 ng of pertussis toxin (PT) was injected intraperitoneally, respectively, to induce an immune response, and to create a classic EAE model.

[0107] 2. Animal Grouping and Drug Intervention

[0108] The EAE model mice injected with MOG antigen emulsion and immunized were randomly divided into 6 groups, and SCH was dissolved in 5% DMSO as a vehicle to make a 0.02% SCH solution for later use; 2-FBI was dissolved in 0.9% normal saline to make a concentration of 0.2 %2-BFI solution for later u...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for treating central nervous system inflammatory demyelinating diseases. The pharmaceutical composition comprises 2-(2-benzofuranyl)-2-imidazoline or a pharmaceutically acceptable salt, a hydrate and a solvate thereof as an active ingredient, and 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-(4, 3-e)-1, 2, 4-triazolo (1, 5-c) pyrimidine or a pharmaceutically acceptable salt, a hydrate and a solvate thereof. The invention further provides a combination containing two medicaments and also provides application of the pharmaceutical composition and the pharmaceutical combination in combined treatment of the central nervous system inflammatory demyelinating diseases, and the synergistic treatment effect is obtained.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a pharmaceutical composition for treating central nervous system inflammatory demyelinating diseases. Background technique [0002] Inflammatory demyelinating diseases of the central nervous system are a very common type of central nervous system autoimmune diseases mediated by T cells, mainly including multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), sub Acute neuromyelitis optica (SMON), concentric sclerosis, central allergic diseases induced by various reasons (such as after infection with various biological pathogens, after vaccination, heterosexual protein allergy, and drug or chemical allergic reaction) ( Such as acute demyelinating leukoencephalopathy and acute demyelinating myelitis), the pathogenesis has not been fully elucidated, and there is currently a lack of specific drug treatment. Experimental autoimmune encephalomyelitis (EAE) animal model is curren...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61K31/4178A61P25/00A61P25/02A61P37/08
CPCA61K31/4178A61K31/519A61K2300/00
Inventor 郑荣远侯圣陶殷为勇张元涛郑浏璞王志强徐惠琴
Owner THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap